

The Manager
Company Announcements
Australian Stock Exchange
4th Floor
20 Bridge Street
SYDNEY NSW 2000

21 April 2008

RHT: Investor Update

Highlights:

- Revenue growth
- Cash flow positive for the quarter
- First reimbursement submission on track for Q2 2008 submission
- UK Clinicians support FerriScan reimbursement
- Countries with high disease prevalence express keen interest in FerriScan[®]

Resonance Health has received approval to extend the provision of FerriScan[®] services to Novartis through the extension of an existing trial and the establishment of a new clinical trial, providing additional revenue of over US\$600,000 between June 2008 and July 2009 and an exciting opportunity to expand the provision of FerriScan[®] to new countries and a growing clinical community.


FerriScan[®] is now available in over 23 countries. Patients with blood disorders such as Thalassaemia, Sickle Cell Anaemia or MDS, often require regular blood transfusions resulting in a build up of excess iron, primarily in the liver. An accurate assessment of the liver iron level enables clinicians to determine the result of the patient's iron reduction therapy and adjust treatment and drug dosing based on accurate information.

Resonance Health continues to successfully pursue its FerriScan[®] commercialisation strategy aimed at:

- obtaining quality and regulatory approvals; *ACHIEVED*
- gaining clinical acceptance with key opinion leaders; *ACHIEVED*
- gaining acceptance in patient management clinical guidelines; *ACHIEVED*
- gaining global covering in service provision. *ACHIEVED*

Having successfully achieved these milestones, Resonance Health is embarking on a targeted marketing strategy tightly linked to achieving reimbursement. A submission to the Australian reimbursement agency is planned for Q2 2008, with the important inclusion of key patient outcome data from a retrospective study currently being performed.

Work has commenced on gaining reimbursement for FerriScan[®] in European countries with high disease prevalence together with strong clinical support for the test. Meetings will be held with UK groups in May to progress the UK reimbursement for FerriScan[®].



Several hospitals in the US have expressed a strong interest in working with Resonance Health to achieve reimbursement for FerriScan[®] making the test more affordable for their patients. Canadian hospitals together with the Canadian Thalassaemia Foundation are also working with us to achieve reimbursement for FerriScan[®] in Canada.

Resonance Health is also working with disease groups in countries such as India, Italy, Germany, Bangladesh and Sri Lanka where disease prevalence can be very high, to provide the FerriScan[®] service to doctors and their patients.

Resonance Health continues to operate in a strong financial position with cash reserves of over AU\$2m and a cash flow positive operation. In addition to the FerriScan[®] test, Resonance Health receives significant revenue from the provision of clinical research support activities including data management and reporting services.

This strong financial position enables the board and management at Resonance Health to pursue new opportunities to create value for shareholders. The company is therefore reviewing a number of initiatives including i) the growth of FerriScan[®] revenues, ii) expanding the provision of clinical research services, iii) broadening the scope of MRI image analysis services and iv) the acquisition of other positive cash flow businesses.

We look forward to updating our shareholders on these initiatives as they progress.

Further information about Resonance Health and FerriScan[®] can be obtained from the web site: www.resonancehealth.com or by sending an email to info@ferriscan.com.

By Order of the Board

Resonance Health Limited